Mitogen-Activated Protein Kinase Inhibitor-Induced Inflammatory Alopecia in Woman With Ovarian Cancer
Journal of Drugs in Dermatology · 2024
DOI: 10.36849/jdd.7802 ↗At a glance
Fallbericht in Journal of Drugs in Dermatology, 2024. Written by Lucy Rose and 4 co-authors. Major MEDLINE topics: Alopecia, Ovarian Neoplasms. Cited 1 times so far (Crossref).
Abstract (original language)
Inflammatory alopecia is an increasingly reported side effect of targeted cancer therapies. Here we report one case of inflammatory alopecia secondary to mitogen-activated protein kinase kinase (MEK) inhibitor agent Trametinib in a woman with ovarian cancer. Biopsies of the scalp were consistent with early scarring alopecia compatible with drug-induced alopecia. Significant improvement in hair loss occurred after treatment with intralesional Kenalog (ILK) injections and oral isotretinoin. Though acute alopecia has been described in patients using MEK inhibitors, this is the first reported case of inflammatory alopecia. J Drugs Dermatol. 2024;23(4):7802. doi:10.36849/JDD.7802e .
Subjects
MeSH terms (MEDLINE)
Substances
Cite
APA
Rose, L., Minta, A., Plaza, J., Cohn, D. E., & Dulmage, B. (2024). Mitogen-Activated Protein Kinase Inhibitor-Induced Inflammatory Alopecia in Woman With Ovarian Cancer. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.7802
Vancouver
Rose L, Minta A, Plaza J, Cohn DE, Dulmage B. Mitogen-Activated Protein Kinase Inhibitor-Induced Inflammatory Alopecia in Woman With Ovarian Cancer. Journal of Drugs in Dermatology. 2024. doi:10.36849/jdd.7802
BibTeX
@article{Rose2024,
author = {Rose, Lucy and Minta, Abena and Plaza, Jose and Cohn, David E and Dulmage, Brittany},
title = {Mitogen-Activated Protein Kinase Inhibitor-Induced Inflammatory Alopecia in Woman With Ovarian Cancer},
journal = {Journal of Drugs in Dermatology},
year = {2024},
doi = {10.36849/jdd.7802}
}
EUVIMED